多发性骨髓瘤 (MM) 是继非霍奇金淋巴瘤之后第二常见的血液癌症。它是通过异常单克隆免疫球蛋白的过量产生来识别的，可导致各种临床症状，如破坏性骨病变、肾功能障碍、贫血和免疫缺陷。本研究旨在评估MM患者血清中羧基末端胶原交联1（CTX-1）、Fibulin-1、维生素D3、LDH和白蛋白的水平及其对早期诊断的意义。这项研究包括30名健康对照（男性11例，女性19例），多发性骨髓瘤患者60例（男性37例，女性23例），年龄在40-60岁之间。采集五毫升血样并保存在-20°C。随后，使用酶联免疫吸附测定 (ELISA) 试剂盒估算 CTX-1、Fibulin-1 和维生素 D3 的浓度。此外，使用自动生化分析仪测定 LDH 和白蛋白水平。这项研究表明，大多数多发性骨髓瘤患者的年龄在 51 岁至 60 岁之间。与健康对照组相比，多发性骨髓瘤患者血清中CTX-1、Fibulin-1和LDH浓度显着升高。相比之下，多发性骨髓瘤患者的血清维生素D3水平显着降低。我们的研究结果表明，男性多发性骨髓瘤的发病率高于女性。此外，与健康对照组相比，多发性骨髓瘤患者的 CTX-1 和 Fibulin-1 血清浓度显着较高，表明它们具有早期检测和作为治疗靶点的潜力。

Multiple myeloma (MM) is the second most prevalent blood cancer after non-Hodgkin lymphoma. It is identified by the excessive production of abnormal monoclonal immunoglobulins, which can result in various clinical symptoms such as destructive bone lesions, renal dysfunction, anemia, and immunodeficiency. The current study aims to evaluate the serum levels of carboxy-terminal collagen crosslinks 1 (CTX-1), Fibulin-1, vitamin D3, LDH, and albumin in MM patients and their significance for early diagnosis.This study included 30 healthy controls (11 males, 19 females) and 60 patients with multiple myeloma (37 males and 23 females), aged between 40-60 years. Five-milliliter blood samples were collected and stored at -20°C. Afterward, enzyme-linked immunosorbent assay (ELISA) kits were used to estimate the concentrations of CTX-1, Fibulin-1, and vitamin D3. Additionally, LDH and albumin levels were determined using the automated biochemistry analyzer.This study revealed that the majority of patients with multiple myeloma are between the ages of 51 and 60 years. The serum concentrations of CTX-1, Fibulin-1, and LDH were significantly increased in the multiple myeloma patients compared to the healthy control group. In contrast, the serum level of vitamin D3 was significantly decreased in patients with MM.Our results indicate that the incidence of multiple myeloma is higher in males than in females. Additionally, the serum concentrations of CTX-1 and Fibulin-1 were significantly higher in the multiple myeloma patients compared to the healthy control group, indicating their potential for early detection and as therapeutic targets.